Lepirudin
- TRADE NAME: Refludan (ZLB Behring)
- INDICATIONS: Anticoagulation in heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease
- CLASS: Anticoagulant, Thrombin inhibitor
- HALF-LIFE: 1.3 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abciximab, Acenocoumarol, Clopidogrel, Eptifibatide, Streptokinase, Thrombolytics, Ticlopidine, Tirofiban, Vitamin K antagonists, Warfarin
PREGNANCY CATEGORY: B
Contra-indicated in patients with a generalized hemostatic abnormality such as
hemophilia, Christmas disease, idiopathic thrombocytopenic purpura and in patients with active bleeding from a local lesion such as acute ulcer or ulcerating carcinoma; in patients who have had recent cranial, spinal, eye or ear surgery or trauma; hypersensitivity to hirudins; shock.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
HEMATOLOGIC.
RESPIRATORY.
OTHER.
Page last updated 08/02/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
